Transave Completes Enrollment in Arikace(TM) Phase II Bronchiectasis Study
... for inhalation) in non-cystic fibrosis (CF) bronchiectasis patients. The results, which are expected to be ... to evaluate Arikace in non-CF patients who have bronchiectasis with Pseudomonas lung infections. In the ... and India are participating in the study. bronchiectasis is characterized by localized, irreversible ...Pharmaxis to Expand Manufacturing Capacity
... Bronchitol for the treatment of diseases including cystic fibrosis, bronchiectasis and chronic bronchitis. Construction of the key manufacturing equipment ... Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD) and PXS64 for the ...Arsenic in Drinking Water Predisposes Children To Lung Cancer in Later Life
... It was found that the risk of dying from bronchiectasis was 46 times more than normal if the child's ... than in the rest of Chile. The risk of death from bronchiectasis was 46 times greater. "In all my career, these ... these the highest death rates for lung cancer and bronchiectasis ever discovered among young adults, but they are ...Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
... infections in cystic fibrosis (CF) and non-CF bronchiectasis patients. Transave announced today that the ... in the treatment of non-CF patients who have bronchiectasis with Pseudomonas lung infections. In the bronchiectasis trial, 64 adult patients were randomized 2:1 to ...12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis
... long term safety of Bronchitol in subjects with bronchiectasis has concluded with no serious adverse events ... deal of interest among people suffering with bronchiectasis and we continue to respond to requests from ... for people with the incurable lung conditions bronchiectasis and cystic fibrosis. It is estimated that more ...Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
... the phase 3 registration trial of Bronchitol for bronchiectasis via the Special Protocol Assessment process. ... renowned experts in the field of bronchiectasis and will be a randomized, placebo controlled, ... III study to be undertaken for Bronchitol in bronchiectasis and follows the completion of a ...Pharmaxis Long-Term Safety Study of Bronchitol Completes
... the safety of Bronchitol in 100 subjects with bronchiectasis has completed. This 12-month treatment period ... in the major pharmaceutical markets suffer from bronchiectasis and Pharmaxis expects Bronchitol to be the first ... U.S. medical care expenditure is US$13,000 per bronchiectasis patient, double that of patients without the ...ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
... more than 600,000 people in the major pharmaceutical markets suffer from bronchiectasis and Pharmaxis expects Bronchitol to be the first targeted medication for ... need. In Australia, it is believed that more than 18,000 people live with bronchiectasis and over 70% are moderately or severely incapacitated by their condition. ...Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
... respiratory and immune disorders. Its development pipeline of products includes Aridol for the diagnosis of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), PXS25 for the treatment of lung fibrosis and PXS4159 for asthma. Founded in 1998, Pharmaxis is ...Pharmaxis Announces New Drug Application Submission for Aridol(TM)
... respiratory and immune disorders. Its development pipeline of products includes Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), PXS25 for the treatment of lung fibrosis and PXS4159 for asthma. Founded in 1998, Pharmaxis is ...Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins
... . Pharmaxis is developing Bronchitol as a treatment to improve mucus clearance in the lungs of patients with cystic fibrosis, bronchiectasis and chronic obstructive airway diseases. Bronchitol is a patented, inhalable dry powder formulation of mannitol that can be administered by ...Transave, Inc. Secures $12.5 Million in New Financing
... trial in a second area of high unmet need: bronchiectasis patients who have pseudomonas lung infections." ... in patients with non-cystic fibrosis-related bronchiectasis in Europe and India. The U.S. Food and ... to expand this trial into the United States. bronchiectasis is the permanent widening of the bronchi (the ...Regulatory Path for Bronchitol in Bronchiectasis
... to be undertaken with Bronchitol in people with bronchiectasis and follows the completion of a successful trial ... advisory board of opinion leading physicians in bronchiectasis and employed clinical and regulatory staff in the ... There are no products specifically approved for bronchiectasis and Bronchitol remains the only product currently ...Pharmaxis' First Steps into China
... trial application for Bronchitol to treat bronchiectasis has been accepted for evaluation by China's State ... that the number of Chinese who suffer from bronchiectasis is more than double that in the rest of ... have indicated they wish to conduct bronchiectasis studies, and have confirmed there is a large ...Pharmaxis to Apply to Market Bronchitol in Australia
... "More than 20,000 Australians suffer from bronchiectasis and Pharmaxis expects Bronchitol to be the first ... years -- addressing an important medical need." bronchiectasis is an incurable, degenerative and chronic lung ... U.S. medical care expenditure is US$13,000 per bronchiectasis patient, double that of patients without the ...Phase III Trial Finds Pharmaxis' Bronchitol Effective
... of Bronchitol for the treatment of people with bronchiectasis has met its two primary efficacy endpoints: ... is the largest single study ever conducted in bronchiectasis and we have collected a large amount of data on a ... With no products currently indicated for bronchiectasis we look forward to discussing our complete data ...Pharmaxis Builds Senior Management Team
... respiratory and immune disorders. Its development pipeline of products includes Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), PXS25 for the treatment of lung fibrosis and PXS4159 for asthma. Founded in 1998, Pharmaxis is ...Chronic Lung Disease - Axentis Pharma Attracts Investment Interest
... aeruginosa. Chronic inflammations then cause lung functions to become blocked. In addition to the breakdown of lung tissue, this also leads to bronchiectasis and lung failure. For further information, please contact: Axentis Pharma AG Limmatquai 138 8001 Zurich Switzerland T: ...Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
... lung diseases including tuberculosis -- A randomized, placebo-controlled trial of inhaled mannitol(Bronchitol) in patients with bronchiectasis -- Cough and airway hyperresponsiveness -- A comparison of inhaled mannitol (Aridol), methacholine provocation and eucapnic voluntary ...Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing
... on track to have Arikace Phase II clinical data in cystic fibrosis patients that have Pseudomonas lung infections this year. In addition, Phase II bronchiectasis data will be available in the first half of 2009," said Tim Whitten, President and Chief Executive Officer of Transave. Tim Whitten further ...